hotspot -WSS

hotspot

author：hotspot 2025-10-01 23:02:59 - browse：6628

Illustration: Alex Hogan/STAT; Photo: Courtesy Perrigo

It’s not every day that a marketing team is tasked with designing the branding and packaging of the first over-the-counter birth control pill to be sold in the U.S.

This was the challenge, and the opportunity, faced by the team behind Opill, the landmark pill from drugmaker Perrigo that received approval from the Food and Drug Administration earlier this month. Their brief: Create a design that would stand out in America’s notoriously sprawling pharmacy aisles; inspire trust and confidence; be easy to remember and recognize; appeal to women — including teenagers — as well as trans men and nonbinary people; clearly communicate its purpose; be simple to carry and use; contain straightforward but accurate user information; and clear FDA requirements.

Settling on the right approach took years of research and testing, which resulted in the name Opill and packaging featuring bright teal, saturated pink, and yellow, as well as a rounded font reminiscent of millennials’ ubiquitous favorite Gotham. All of these features are intended to set the product apart from the dozens of prescription contraceptive pills available in the U.S. market and internationally.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： How housing is health care on Long Island

knowledge

WSS

Walmart eyes Medicare Advantage provider ChenMed

New weight loss drugs work. But how can they best be used?

PEPFAR is under serious threat — and so is global health

WATCH: Why do bright lights make us see spots?

A single drug, study failures leave Anavex with nothing but cash

Diverse clinical trials: Why aren’t we there yet?

leisure time

hotspot

explore

Cancer drug shortages should be causing more outrage

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Supreme Court strikes down use of affirmative action

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

United colonoscopy coverage change 'may cost lives,' doctors say

Diverse clinical trials: Why aren’t we there yet?

Dobbs anniversary: the lost opportunity of abortion as health care

Antibiotic resistance and the global rise in human conflict

Trump demands the U.S. pay no more for drugs than other countries … again

Pig kidney works a record two months in donated body

leisure time

Goldman Sachs launches $650M fund for life science investments

Generate Biomedicines machine learning biotech raises $273M

JPM: CVS says Medicare Advantage patients are impacting profits

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Burning questions for the 2024 JPM Healthcare Conference

Generate Biomedicines machine learning biotech raises $273M

focus

knowledge

hotspot

entertainment